COMPARISON
Carfilzomib vs Exenatide
6 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Carfilzomib is authorised or registered in 10 and Exenatide in 5 of the 10 registers read. Carfilzomib: highest phase Phase 3 (14 phase 3 trials, 0 with posted results). Exenatide: highest phase Phase 2. 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Carfilzomib | Exenatide | |
|---|---|---|
| Registered trials differs | 308 clinicaltrials.gov · 2026-10-03 | 383 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: KYPROLIS openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Withdrawn ema · 2026-10-03 |
| EU authorised on differs | 2015-11-19 ema · 2026-10-03 | Not checked no record of "authorisedOn" for exenatide |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for carfilzomib | 2024-11-20 ema · 2026-10-03 |
| ATC code differs | L01XX45 ema · 2026-10-03 | A10BJ01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Carfilzomib | placebo | Exenatide | placebo |
|---|---|---|---|---|
| Headache | - | - | 1.9% | 1.3% |
| Non-cardiac chest pain | - | - | 1.1% | 1.0% |
| Osteoarthritis | - | - | 0.9% | 1.0% |
| Dizziness | - | - | 0.8% | 0.4% |
| Constipation | - | - | 0.8% | 0.3% |
| Dyspepsia | - | - | 0.8% | 0.3% |
| Chronic obstructive pulmonary disease | - | - | 0.7% | 0.7% |
| Fatigue | - | - | 0.6% | 0.1% |
| Back pain | - | - | 0.5% | 0.6% |
| Sinusitis | - | - | 0.5% | 0.2% |
Trial register Carfilzomib: 0 placebo-controlled trials; Exenatide: 24. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Carfilzomib side effects · Exenatide side effects
LEGAL STATUS
Approval in each country read
| Country | Carfilzomib | Exenatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Withdrawn | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.